the "Bolla" trial of long term ADT updated

Lancet Oncology:

The "Bolla" trial of Long Term ADT for prostate cancer is updated, with the DFS and OS benefit confirmed out to 10 years. What is also reassuring in this update is that the cardiovascular mortality was not increased with LHRH agonists.

Link:

[Articles] External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study: "In patients with prostate cancer with high metastatic risk, immediate androgen suppression with an LHRH agonist given during and for 3 years after external irradiation improves 10-year disease-free and overall survival without increasing late cardiovascular toxicity."